Blood stage merozoite surface protein conjugated to nanoparticles induce potent parasite inhibitory antibodies

Vaccine

Volumn 29, Issue 48, 2011, Pages 8898-8908

  Pusic, Kae ^a   Xu, Hengyi ^b   Stridiron, Andrew ^a   Aguilar, Zoraida ^b   Wang, Andrew ^b   Hui, George ^a  

^a UNIVERSITY OF HAWAII   (United States)

^b Oceannanotech LLC   (United States)

Author keywords

Adjuvant; Dendritic cells; Inhibitory antibodies; Malaria vaccine; Nanoparticles

Indexed keywords

MALARIA VACCINE; NANOPARTICLE; QUANTUM DOT; RECOMBINANT ANTIGEN; RECOMBINANT MEROZOITE SURFACE PROTEIN 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY RESPONSE; ARTICLE; BLOOD; CYTOKINE RELEASE; DENDRITIC CELL; DRUG ANTIGENICITY; DRUG DELIVERY SYSTEM; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MALARIA; MALE; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; CYTOKINES; DENDRITIC CELLS; FEMALE; IMMUNOGLOBULIN G; MALARIA VACCINES; MALARIA, FALCIPARUM; MEROZOITE SURFACE PROTEIN 1; MICE; MICE, INBRED C57BL; NANOPARTICLES; PLASMODIUM FALCIPARUM; QUANTUM DOTS; RECOMBINANT PROTEINS; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 82455218940     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.09.070     Document Type: Article

References (60)

1. Kumar S., Collins W., Egan A., Yadava A., Garraud O., Blackman M.J., et al. Immunogenicity and efficacy in aotus monkeys of four recombinant Plasmodium falciparum vaccines in multiple adjuvant formulations based on the 19-kilodalton C terminus of merozoite surface protein 1. Infect Immun 2000, 68(4):2215-2223.
2. Holder A.A., Guevara Patino J.A., Uthaipibull C., Syed S.E., Ling I.T., Scott-Finnigan T., et al. Merozoite surface protein 1, immune evasion, and vaccines against asexual blood stage malaria. Parassitologia 1999, 41(1-3):409.
3. Singh S., Miura K., Zhou H., Muratova O., Keegan B., Miles A., et al. Immunity to recombinant Plasmodium falciparum Merozoite Surface Protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with Anti-MSP1 antibody titer and in vitro parasite-inhibitory activity. Infect Immun 2006, 74(8):4573.
4. Chang S.P., Case S.E., Gosnell W.L., Hashimoto A., Kramer K.J., Tam L.Q., et al. A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria. Infect Immun 1996, 64(1):253.
5. Stowers A.W., Cioce V., Shimp R.L., Lawson M., Hui G., Muratova O., et al. Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial. Infect Immun 2001, 69(3):1536.
6. Holder A.A., Blackman M.J., Burghaus P.A., Chappel J.A., Ling I.T., McCallum-Deighton N., et al. A malaria merozoite surface protein (MSP1)-structure, processing and function. Mem Inst Oswal Cruz 1992, 87(Suppl. 3):37.
7. Holder A.A., Freeman R.R. The three major antigens on the surface of Plasmodium falciparum merozoites are derived from a single high molecular weight precursor. J Exp Med 1984, 160(2):624-629.
8. Burghaus P.A., Wellde B.T., Hall T., Richards R.L., Egan A.F., Riley E.M., et al. Immunization of Aotus nancymai with recombinant C terminus of Plasmodium falciparum merozoite surface protein 1 in liposomes and alum adjuvant does not induce protection against a challenge infection. Infect Immun 1996, 64(9):3614-3619.
9. Egan A.F., Burghaus P., Druilhe P., Holder A.A., Riley E.M. Human antibodies to the 19kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro. Parasite Immunol 1999, 21(3):133.
10. Al Yaman F., Genton B., Kramer K.J., Chang S.P., Hui G.S., Baisor M., et al. Assessment of the role of naturally acquired antibody levels to Plasmodium falciparum merozoite surface protein-1 in protecting Papua New Guinean children from malaria morbidity. Am J Trop Med Hyg 1996, 54(5):443-448.
11. John C.C., O'Donnell R.A., Sumba P.O., Moormann A.M., de Koning-Ward T.F., King C.L., et al. Evidence that invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein-1 (MSP-1 19) can play a protective role against blood-stage Plasmodium falciparum infection in individuals in a malaria endemic area of Africa. J Immunol 2004, 173(July (1)):666-672.
12. O'Donnell R.A., Koning-Ward T.F., Burt R.A., Bockarie M., Reeder J.C., Cowman A.F., et al. Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria. J Exp Med 2001, 193(12):1403-1412.
13. Perraut R., Marrama L., Diouf B., Sokhna C., Tall A., Nabeth P., et al. Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese village. J Infect Dis 2005, 191(2):264-271.
14. Ogutu B.R., Apollo O.J., McKinney D., Okoth W., Siangla J., Dubovsky F., et al. Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS One 2009, 4(3):e4708.
15. Angov E., Bergman-Leitner E.S., Duncan E.H., Brent-Kirk A., McCasland M., Mease R., et al. Measurement of antibody fine specificities induced by malaria vaccine FMP1/ASO2A from a pediatric phase 2B trial in western Kenya. Am J Trop Med Hyg 2007, 77(5 Suppl.). [abstract 12].
16. Ellis RD, Martin LB, Shaffer D, Long CA, Miura K, Fay MP, et al. Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naive adults. PLoS One 2010;5(1):e8787.
17. Malkin E., Long C.A., Stowers A.W., Zou L., Singh S., MacDonald N.J., et al. Phase 1 study of two merozoite surface protein 1 (MSP1(42)) vaccines for Plasmodium falciparum malaria. PLoS Clin Trials 2007, 2(4):e12.
18. Stoute J.A., Gombe J., Withers M.R., Siangla J., McKinney D., Onyango M., et al. Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya. Vaccine 2007, 25(January (1)):176-184.
19. O'Hagan D.T., Singh M. Microparticles as vaccine adjuvants and delivery systems. Expert Rev Vaccines 2003, 2(April (2)):269-283.
20. O'Hagan D.T., Singh M., Ulmer J.B. Microparticle-based technologies for vaccines. Methods 2006, 40(September (1)):10-19.
21. Peek L.J., Middaugh C.R., Berkland C. Nanotechnology in vaccine delivery. Adv Drug Deliv Rev 2008, 60(8):915-928.
22. Singh M., Chakrapani A., O'Hagan D. Nanoparticles microparticles as vaccine-delivery systems. Expert Rev Vaccines 2007, 6(5):797-808.
23. Bramwell V.W., Perrie Y. Particulate delivery systems for vaccines. Crit Rev Ther Drug Carrier Syst 2005, 22(2):151-214.
24. Mundargi R.C., Babu V.R., Rangaswamy V., Patel P., Aminabhavi T.M. Nano/micro technologies for delivering macromolecular therapeutics using poly(d,l-lactide-co-glycolide) and its derivatives. J Control Release 2008, 125(3):193-209.
25. Lu J.M., Wang X., Marin-Muller C., Wang H., Lin P.H., Yao Q., et al. Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn 2009, 9(4):325-341.
26. Akagi T., Wang X., Uto T., Baba M., Akashi M. Protein direct delivery to dendritic cells using nanoparticles based on amphiphilic poly(amino acid) derivatives. Biomaterials 2007, 28(23):3427-3436.
27. Shive M.S., Anderson J.M. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 1997, 28(1):5-24.
28. Ludwig C., Wagner R. Virus-like particles-universal molecular toolboxes. Curr Opin Biotechnol 2007, 18(6):537-545.
29. Chackerian B. Virus-like particles: flexible platforms for vaccine development. Expert Rev Vaccines 2007, 6(3):381-390.
30. Skene C.D., Sutton P. Saponin-adjuvanted particulate vaccines for clinical use. Methods 2006, 40(1):53-59.
31. Sun H.X., Xie Y., Ye Y.P. ISCOMs and ISCOMATRIX. Vaccine 2009, 27(33):4388-4401.
32. Masotti A., Ortaggi G. Chitosan micro- and nanospheres: fabrication and applications for drug and DNA delivery. Mini Rev Med Chem 2009, 9(4):463-469.
33. van dLI, Verhoef J.C., Borchard G., Junginger H.E. Chitosan for mucosal vaccination. Adv Drug Deliv Rev 2001, 52(2):139-144.
34. Illum L., Jabbal-Gill I., Hinchcliffe M., Fisher A.N., Davis S.S. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev 2001, 51(1-3):81-96.
35. Ueno Y., Futagawa H., Takagi Y., Ueno A., Mizushima Y. Drug-incorporating calcium carbonate nanoparticles for a new delivery system. J Control Release 2005, 103(1):93-98.
36. Kaba S.A., Brando C., Guo Q., Mittelholzer C., Raman S., Tropel D., et al. A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria. J Immunol 2009, 183(December (11)):7268-7277.
37. Xu H., Aguilar Z.P., Su H.P., Dixon J.D., Wei H., Wang A.Y. Breast cancer cell imaging using semiconductor quantum dots. ECS Trans 2009, 25(11):69-77.
38. Xu H., Aguilar Z.P., Wang A.Y. Quantum dot based sensors for proteins. ECS Trans 2010, 25(31):1-8.
39. Xu H., Wei H., Aguilar Z.P., Waldron J.L., Wang A.Y. Application of semiconductor quantum dots for breast cancer cell sensing. IEEE 2009.
40. Gao X., Cui Y., Levenson R.M., Chung L.W., Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 2004, 22(August (8)):969-976.
41. Kirkpatrick R.B., Shatzman A., Fernandez J., Hoeffler J. Drosophila S2 System for heterologous gene expression. Gene expression systems: using nature for the art of expression 1999, vol. 28. Academic Press, p. 9-330.
42. Chang S.P., Gibson H.L., Lee-Ng C.T., Barr P.J., Hui G.S. A carboxyl-terminal fragment of Plasmodium falciparum gp195 expressed by a recombinant baculovirus induces antibodies that completely inhibit parasite growth. J Immunol 1992, 149(2):548-555.
43. Hui G.S., Hashimoto A.C., Nikaido C.M., Choi J., Chang S.P. Induction of antibodies to the Plasmodium falciparum merozoite surface protein-1 (MSP1) by cross-priming with heterologous MSP1s. J Immunol 1994, 153(August (3)):1195-1201.
44. Chang S.P., Hui G.S., Kato A., Siddiqui W.A. Generalized immunological recognition of the major merozoite surface antigen (gp195) of Plasmodium falciparum. Proc Natl Acad Sci USA 1989, 86(August (16)):6343-6347.
45. Hui G.S., Gosnell W.L., Case S.E., Hashiro C., Nikaido C., Hashimoto A., et al. Immunogenicity of the C-terminal 19-kDa fragment of the Plasmodium falciparum merozoite surface protein 1 (MSP1), YMSP1(19) expressed in S. cerevisiae. J Immunol 1994, 153(15 (6)):2544-2553.
46. Siddiqui W.A., Tam L.Q., Kramer K.J., Hui G.S., Case S.E., Yamaga K.M., et al. Merozoite surface coat precursor protein completely protects Aotus monkeys against Plasmodium falciparum malaria. Proc Natl Acad Sci USA 1987, 84(May (9)):3014-3018.
47. Hui G., Choe D., Hashimoto C. Biological activities of anti-merozoite surface protein-1 antibodies induced by adjuvant-assisted immunizations in mice with different immune gene knockouts. Clin Vaccine Immunol 2008, 15(August (8)):1145-1150.
48. Hui G., Hashimoto C. The requirement of CD80, CD86, and ICAM-1 on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccine. Vaccine 2007, 25(12 (51)):8549-8556.
49. Leung W.H., Meng Z.Q., Hui G., Ho W.K. Expression of an immunologically reactive merozoite surface protein (MSP-1(42)) in E. coli. Biochim Biophys Acta 2004, 1675(November (1-3)):62-70.
50. Pang A.L., Hashimoto C.N., Tam L.Q., Meng Z.Q., Hui G.S., Ho W.K. In vivo expression and immunological studies of the 42-kilodalton carboxyl-terminal processing fragment of Plasmodium falciparum merozoite surface protein 1 in the baculovirus-silkworm system. Infect Immun 2002, 70(June (6)):2772-2779.
51. Inaba K., Inaba M., Romani N., Aya H., Deguchi M., Ikehara S., et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992, 176(December (6)):1693-1702.
52. Szymczak WA, Deepe GS, Jr., Antigen-presenting dendritic cells rescue CD4-depleted CCR2-/- mice from lethal Histoplasma capsulatum infection. Infect Immun 2010;78(May(5)):2125-37.
53. Hui G., Hashimoto C. Plasmodium falciparum anti-MSP 1-19 antibodies induced by MSP 1-42 and MSP 1-19 based vaccines differed in specificity and parasite growth inhibition in terms of recognition of conserved versus variant epitopes. Vaccine 2007, 25(January (5)):948-956.
54. Hui G.S., Hashimoto C.N. Adjuvant formulations possess differing efficacy in the potentiation of antibody and cell mediated responses to a human malaria vaccine under selective immune genes knockout environment. Int Immunopharmacol 2008, 8(July (7)):1012-1022.
55. Quinnell R.J., Bethony J., Pritchard D.I. The immunoepidemiology of human hookworm infection. Parasite Immunol 2004, 26(November-December (11-12)):443-454.
56. Infante-Duarte C., Kamradt T. Th1/Th2 balance in infection. Springer Semin Immunopathol 1999, 21(3):317-338.
57. Shahiwala A., Vyas T.K., Amiji M.M. Nanocarriers for systemic and mucosal vaccine delivery. Recent Pat Drug Deliv Formul 2007, 1(1):1-9.
58. Champion C.I., Kickhoefer V.A., Liu G., Moniz R.J., Freed A.S., Bergmann L.L., et al. A vault nanoparticle vaccine induces protective mucosal immunity. PLoS One 2009, 4(4):e5409.
59. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005, 5(3):161-171.
60. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2(12):751-760.